Jeffrey S. Heier
NEW ORLEANS — Lampalizumab failed to impact geographic area compared with sham treatment in two identically designed phase 3 studies — Chroma and Spectri, according to a speaker.
Giving 48-week topline results of the Spectri trial of lampalizumab at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting, Jeffrey S. Heier, MD, said, “Lampalizumab did not reduce GA area change from baseline. The primary endpoint was not met. Lampalizumab was not effective in reducing GA lesion growth. Chroma also demonstrated no treatment benefit of
Uncategorized